Kaitlyn D’Onofrio

DocwireNews

<p>For the first time, the Food and Drug Administration (FDA) has approved the Monarch external Trigeminal Nerve Stimulation (eTNS) System a non-drug device treatment for children with attention deficit hyperactivity disorder (ADHD). Here are four fast facts about the device:<ol>
<li>The device is called the Monarch external Trigeminal Nerve Stimulation (eTNS) System and is marketed by NeuroSigma. Only available by prescription, it is indicated for ADHD patients aged between seven and 12 years old not currently taking prescription ADHD medication.</li>
<li>Use of the Monarch eTNS system must be monitored by a caregiver.</li>
<li>It is about the size of a cell phone and works by sending the patient a low-level electrical pulse through a wire connected to a patch placed on the patient&rsquo;s forehead&mdash;while the patient is asleep. It creates &ldquo;a tingling sensation on the skin,&rdquo; according to the FDA. It may take up to four weeks to take effect.</li>
<li>While the mechanisms behind eTNS are not entirely understood, previous data have shown that eTNS stimulates brain activity in areas that involve attention, emotion, and behavior.</li>
</ol><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">The first medical device to treat children with ADHD has been approved by the FDA. <a href="https://t.co/g8y47ppfkg">https://t.co/g8y47ppfkg</a> <a href="https://t.co/TQOWzlHbqn">pic.twitter.com/TQOWzlHbqn</a></p>
<p>&mdash; WebMD (@WebMD) <a href="https://twitter.com/WebMD/status/1120447189560569857?ref_src=twsrc%5Etfw">April 22, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>&ldquo;This new device offers a safe, non-drug option for treatment of ADHD in pediatric patients through the use of mild nerve stimulation, a first of its kind,&rdquo; said Carlos Pe&ntilde;a, PhD, director of the Division of Neurological and Physical Medicine Devices in the FDA&rsquo;s Center for Devices and Radiological Health, in the FDA&rsquo;s statement. &ldquo;[The approval] reflects our deep commitment to working with device manufacturers to advance the development of pediatric medical devices so that children have access to innovative, safe and effective medical devices that meet their unique needs.&rdquo;</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">The FDA has cleared for marketing the first medical device, known as the Monarch external trigeminal nerve stimulation system, to treat attention-deficit/hyperactivity disorder (<a href="https://twitter.com/hashtag/ADHD?src=hash&amp;ref_src=twsrc%5Etfw">#ADHD</a>).</p>
<p>&mdash; PhysiciansFirstWatch (@Physns1stWatch) <a href="https://twitter.com/Physns1stWatch/status/1120478331269451777?ref_src=twsrc%5Etfw">April 23, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><h2><strong>Small Clinical Trial Demonstrates Safety, Efficacy</strong></h2><p>The effectiveness of trigeminal nerve stimulation (TNS) in treating ADHD was evaluated in a double-blind, sham-controlled study published in the April issue of the <em>Journal of the American Academy of Child &amp; Adolescent Psychiatry</em>. The trial included 62 children aged between eight and 12 years old with a full-scale IQ &ge; 85 and Schedule for Affective Disorders and Schizophrenia&ndash;diagnosed ADHD. Patients randomly received four weeks of daily active or sham TNS treatment and one week of no intervention. Patients underwent ADHD Rating Scales (ADHD-RS) and Clinical Global Impression (CGI) scales assessments each week, as well as baseline and four-week quantitative electroencephalography.</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">FDA signs off on 1st non drug device for treating <a href="https://twitter.com/hashtag/ADHD?src=hash&amp;ref_src=twsrc%5Etfw">#ADHD</a> in children. The Monarch external Trigeminal Nerve Stimulation (eTNS) System, (prescription-only) is for children ages 7 /12 who are not currently taking ADHD prescription medication. <a href="https://t.co/Ju5uJmh1kE">https://t.co/Ju5uJmh1kE</a> via <a href="https://twitter.com/USATODAY?ref_src=twsrc%5Etfw">@usatoday</a></p>
<p>&mdash; C. Michael Gibson MD (@CMichaelGibson) <a href="https://twitter.com/CMichaelGibson/status/1119943196912553984?ref_src=twsrc%5Etfw">April 21, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">FDA Approves Digital Health Treatment for Children Living With ADHD <a href="https://t.co/0tfSHLhmch">https://t.co/0tfSHLhmch</a></p>
<p>&mdash; David Lee Scher, MD (@dlschermd) <a href="https://twitter.com/dlschermd/status/1120465613443543040?ref_src=twsrc%5Etfw">April 22, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>The researchers observed significant improvement in ADHD-RS total scores: &ldquo;At the end of week four, the average ADHD-RS score in the active group decreased from 34.1 points at baseline to 23.4 points, versus a decrease from 33.7 to 27.5 points in the placebo group,&rdquo; the FDA wrote in its statement.</p><p>The study authors also reported improved CGI-Improvement scores in active TNS patients. &ldquo;Resting-state quantitative electroencephalography showed increased spectral power in the right frontal and frontal midline frequency bands with active TNS,&rdquo; they further observed, adding that no significant adverse events took place.</p><p>The FDA listed drowsiness, increased appetite, trouble sleeping, teeth clenching, headache, and fatigue as the most common side effects.</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Say it isn&rsquo;t true that <a href="https://twitter.com/US_FDA?ref_src=twsrc%5Etfw">@US_FDA</a> approved Trigeminal nerve stimulation for ADHD based on a single trial of only 62 children (divided on two conditions) with not more than 4 weeks follow-up. <a href="https://t.co/HPsxWoWnVO">https://t.co/HPsxWoWnVO</a></p>
<p>&mdash; Joar &Oslash;veraas Halvorsen (@joarhalvorsen) <a href="https://twitter.com/joarhalvorsen/status/1120739509837205504?ref_src=twsrc%5Etfw">April 23, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">FDA Allows Marketing of ADHD Treatment Device<a href="https://twitter.com/AmerMedicalAssn?ref_src=twsrc%5Etfw">@AmerMedicalAssn</a>  <a href="https://twitter.com/AmerAcadPeds?ref_src=twsrc%5Etfw">@AmerAcadPeds</a> <a href="https://t.co/j2OExFCzw7">https://t.co/j2OExFCzw7</a></p>
<p>&mdash; Joseph N Macaluso MD FACS (@MacalusoJoseph) <a href="https://twitter.com/MacalusoJoseph/status/1120741337001799681?ref_src=twsrc%5Etfw">April 23, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p></p>


Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Four Facts About the First FDA-approved Non-drug ADHD Treatment

Neurodivergent

For the first time, the Food and Drug Administration (FDA) has approved a non-drug treatment for children with attention deficit hyperactivity disorder (ADHD). Here are four ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe